Previous close | 21.83 |
Open | 13.80 |
Bid | 10.20 |
Ask | 16.50 |
Strike | 435.00 |
Expiry date | 2024-05-31 |
Day's range | 13.80 - 13.80 |
Contract range | N/A |
Volume | |
Open interest | 41 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.